Abstract
In this paper, we propose an enhanced SEIRD (Susceptible-Exposed-Infectious-Recovered-Death) model with time varying case fatality and transmission rates for confirmed cases and deaths from COVID-19. We show that when case fatalities and transmission rates are represented by simple Sigmoid functions, historical cases and fatalities can be fit with a relative-root-mean-squared-error accuracy on the order of 2% for most American states over the period from initial cases to July 28 (2020). We find that the model is most accurate for states that so far had not shown signs of multiple waves of the disease (such as New York), and least accurate for states where transmission rates increased after initially declining (such as Hawaii). For such states, we propose an alternate multi-phase model. Both the base model and multi-phase model provide a way to explain historical reported cases and deaths with a small set of parameters, which in the future can enable analyses of uncertainty and variations in disease progression across regions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ML and RH's work is supported by the Zumberge Research & Innovation Fund of the University of Southern California (no grant number is assigned). The funder played no role in study design.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
mingdonl{at}usc.edu(ML); rwhall{at}usc.edu(RH)
Data Availability
All data are fully available without restriction